The WoVen Podcast
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2024 Canaan |
Latest for Nocion
FierceBiotech: COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread
40% of patients who recover from COVID-19 in hospital get sent home with a postviral cough that lasts three to eight weeks. Containing those coughs, or stopping them altogether, could play a role in curbing the spread of the virus.
FierceBiotech: Nocion Therapeutics named to Fierce 15
While whole shoals of biotechs are clustered around single cancer targets, Nocion is away from the pack working on better ways to treat conditions...
Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation
Today, Canaan proudly introduces Nocion Therapeutics, a Series A neurogenic inflammation and analgesic company discovering and developing novel...
Fierce Biotech: Nocion grabs new CMO as it kicks off COVID-19 cough study
Business Insider: Meet the 21 biotech startups that top VCs say are poised to take off in the next 12 months
FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain
Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up
STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain